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Purpose: To compare the Cambridge contrast sensitivity (CS) test and visual evoked 
potentials (VEP) in detecting visual impairment in a population of visually symptomatic 
and asymptomatic patients affected by clinically definite multiple sclerosis (MS).
Methods: Fifty patients (100 eyes) presenting with MS and 25 healthy subjects (50 eyes) 
with normal corrected visual acuity were included in this study. CS was determined 
using the Cambridge Low Contrast Grating test and VEP was obtained in all eyes. 
Findings were evaluated in two age strata of 10-29 and 30-49 years.
Results: Of the 42 eyes in the 10-29 year age group, CS was abnormal in 22 (52%), 
VEP was also abnormal in 22 (52%), but only 12 eyes (28%) had visual symptoms. Of 
the 58 eyes in the 30-49 year group, CS was abnormal in 7 (12%), VEP was abnormal 
in 34 (58%), while only 11 eyes were symptomatic. No single test could detect all of 
the abnormal eyes.
Conclusion: The Cambridge Low Contrast Grating test is useful for detection of 
clinical and subclinical visual dysfunction especially in young patients with multiple 
sclerosis. Nevertheless, only a combination of CS and VEP tests can detect most cases 
of visual dysfunction associated with MS.
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INTRODuCTION
Patients with multiple sclerosis (MS) often 
demonstrate visual dysfunction which may 
be clinical or subclinical. The detection of 
occult visual loss is important in establishing 
a diagnosis of multiple sclerosis, especially 
in patients who have neurological symptoms 
of the disease. Snellen acuity loss, color 
deficiencies, static perimetric defects, and optic 
atrophy are characteristic findings following 
optic neuritis.1 In many patients with multiple 
sclerosis, conventional visual tests (i.e., visual 
acuity and visual fields) may not detect all 
functional visual deficits. In some MS patients 
visual acuity may be normal even when 
patients complain of poor vision which they 
often describe as “blurred” or “washed out”.2 
Subtle visual abnormalities may be revealed 
by more specific examinations.1 Alteration 
in visual evoked potential (VEP) latencies 
using pattern stimuli is considered one of the 
most characteristic electrophysiological signs 
observed in patients with MS. Additionally, 
subjective psychophysical tests such as contrast 
sensitivity (CS) have been reported to be useful CS vs. VEP in Multiple Sclerosis; Heravian et al
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in detection of visual abnormalities, but have 
been judged to be more or less sensitive than 
other methods according to different studies.3
Contrast sensitivity is defined as the 
threshold contrast at which a faint pattern of 
stripes is just visible. Impairment of CS has been 
demonstrated in a variety of disorders associated 
with visual loss. CS testing unmasks “hidden 
visual loss” in multiple sclerosis and has been 
proposed as a simple and rapid screening test 
for subclinical optic neuropathy.4
In this study we compare the Cambridge CS 
test and VEP for detection of visual dysfunction 
in a population of visually symptomatic and   
asymptomatic patients with clinically definite MS.
METHODS
Fifty patients (100 eyes) diagnosed with 
clinically definite multiple sclerosis and normal 
or corrected-to-normal Snellen acuity (6/6) were 
selected from a neurology clinic; 39 patients 
were female, 11 were male and mean age was 
30.8±5.7 (range, 17-45) years.
Normative data for CS and VEP were 
derived from 25 age-matched subjects with 
normal Snellen acuity who were selected from 
students and patients with non-neurological 
disease. These control subjects included 19 
female and 6 male individuals with mean age of 
29.5±5.6 (range, 19-41) years. All control subjects 
and patients underwent VEP and CS testing. 
None of the controls had ocular abnormalities 
affecting contrast sensitivity. Furthermore, all 
eyes had Snellen acuity of 6/6 or more, after 
full optical correction.
Contrast sensitivity was assessed using the 
Cambridge Low Contrast Grating test5 (Clement 
Clarke, London, UK) at a viewing distance of 6 
meters with full correction, if necessary. Each 
eye was tested separately. This test includes 12 
pairs of plates. The luminance of the test plates 
is about 100cd/m2. Series of plate pairs were 
presented in order of increasing difficulty to a 
total of four times for each eye. The observer was 
told to choose whether the top or bottom plate 
contained the grating, guessing if necessary. 
Using a conversion table, the maximum possible 
score was recorded for each eye.
VEP was recorded using the Toennies 
Neuroscreen (Jaeger-Toennies Inc., Höchberg, 
Germany). VEPs were elicited by checkerboards 
reversing at 1 Hz (2 reversals per second) on a 
television monitor located 1m from the patient. 
The VEP program provides a checkerboard 
pattern sized 15 minutes of arc for visual 
stimulation6. Checkerboard contrast was 80% 
with luminance of 89 cd/m2. VEP was recorded 
by means of bipolar midline derivation with 
the active electrode located 2.5 cm above the 
inion referenced to the center of the forehead 
with a ground electrode attached to the right 
wrist by a clip. The amplifier bandwidth filters 
were set at 1.0-100 Hz. VEP waves, consisting 
of 300 sweeps, were randomly recorded for 
each eye. Averages were plotted on an x-plotter 
and measured latencies were compared with 
norms. VEP measurements were obtained with 
the patient wearing a visual aid, if needed 
and the fellow eye was occluded. A fixation 
spot was used on the center of the screen 
during stimulation. The latency of the first 
major positive peak in the VEP (P100 wave) 
was measured. Most investigators currently 
interpret pattern reversal VEP (P-VEP) based 
almost entirely on latency of P100.
Whenever applicable, paired sample and 
independent t-tests were performed to compare 
means. P-values less than 0.05 were considered 
as significant. Cohen’s Kappa coefficient was 
used to measure inter-rater agreement among 
parameters in eyes with abnormal CS, delayed 
VEP and visual symptoms.
RESuLTS
Patients and control subjects were divided into 
two age strata of 10-29 and 30-49 years. Of 50 
patients (100 eyes) with clinically definite MS, 
21 subjects (42 eyes) were aged 10-29 years and 
29 others (58 eyes) were 30-49 years of age. 
CS and VEP scores of control subjects were 
recorded in order to determine the normal 
limits (2 standard deviations from the mean 
value) within each group. Mean and standard 
deviations for CS and P100 latency in both age 
groups in controls and patients are shown 
in Table 1. Contrast sensitivity scores in all CS vs. VEP in Multiple Sclerosis; Heravian et al
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control subjects but one (96%) were within 
normal range. All control subjects (100%) had 
normal P100 latencies. It should be noted that 
the normal VEP latency in this study was less 
than 114 msec.
Of the 42 eyes in the 10-29 year age group, 
CS was abnormal in 22 eyes (52%), VEP was 
also abnormal in 22 eyes (52%), but only 12 
eyes (29%) had visual symptoms. Ten out of 
42 eyes (24%) had both abnormal CS and VEP, 
12 eyes (29%) only had an abnormal CS and 
12 others (29%) only had an abnormal VEP. 
Eight eyes (18%) demonstrated no abnormality 
on either test.
Of 58 eyes in the 30-49 year age group, 
CS was abnormal in 7 eyes (12%), whereas 
VEP was abnormal in 34 eyes (59%), but only 
11 eyes (19%) were symptomatic. Four out of 
58 eyes (7%) had both an abnormal CS and 
VEP, 3 eyes (5%) only had an abnormal CS 
and 30 others (52%) only had an abnormal 
VEP. Twenty-one (36%) eyes demonstrated no 
abnormality on either test.
The association between abnormal VEP and 
CS tests was not statistically significant in any 
of the study groups. There was a statistically 
significant decrease in contrast sensitivity with 
age (P<0.001), whereas no significant trend was 
observed for VEP latency or visual symptoms 
as a function of age.
In the young age group, among 22 eyes 
with abnormal CS, 12 (55%) were visually 
symptomatic and 10 (45%) were asymptomatic. 
In the same group, of 22 eyes with abnormal 
VEP, only 5 (23%) had visual symptoms and 
17 (77%) were asymptomatic (Fig. 1).
In the older age group, among 7 eyes with 
abnormal CS, 3 (43%) were symptomatic and 4 
(57%) were asymptomatic. In the same group, 
among 34 eyes with abnormal VEP, only 8 
(24%) had visual symptoms and 26 (76%) were 
asymptomatic (Fig. 2).
Age groups












10-29 456±89 286±143 P<0.001 105±5 114±21 P=0.315
30-49 320±67 293±139 P=0.551 104±3 124±22 P<0.001
LE
10-29 461±96 282±137 P<0.001 105±5 114±18 P=0.075
30-49 339±103 301±123 P=0.368 104±3 121±21 P=0.015
Bin
10-29 531±48 327±123 P<0.001
30-49 476±75 357±132 P=0.006
Table 1. Mean values and standard deviations of contrast sensitivity and P100 latency in normal controls and multiple 
sclerosis patients stratified by age
SD, standard deviation; RE, right eye; LE, left eye; Bin, binocular
Figure 1.  The  frequency  of  symptomatic  and 
asymptomatic eyes in patients with abnormal CS and 
VEP in the 10-29 year age group.
Figure 2.  The  frequency  of  symptomatic  and 
asymptomatic eyes in patients with abnormal CS and 
VEP in the 30-49 year age group.CS vs. VEP in Multiple Sclerosis; Heravian et al
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The correlation between abnormal CS and 
visual symptoms such as blurred vision was 
significant only in the 10-29 year age group 
(kappa=0.533, P=0.001). Visual symptoms and 
delayed VEP failed to show any significant 
correlation in either of the age strata.
The prevalence of abnormalities in 
monocular and binocular contrast sensitivity 
was the same in the 10-29 year age group 
(13 out of 21 patients, 62%). In the 30-49 year 
age group, only 5 out of 29 patients (17%) had 
abnormal monocular CS, whereas abnormal 
binocular CS was observed in 13 of the 29 
patients (45%) in this age group. The comparison 
between abnormal monocular and binocular 
CS indicated a significant difference in this 
age group (P<0.001). No significant decrease 
in binocular contrast sensitivity was noted 
with age.
Considering both eyes of each patient 
together, of 21 patients in the young age group, 
CS was abnormal in 13 (62%) and VEP was 
abnormal in 15 (71%) subjects in one or both 
eyes. Of 29 patients in the older age group, CS 
was abnormal in 5 (17%) and VEP was delayed 
in 20 (69%) subjects in one or both eyes. When 
both tests were taken together, 90% of patients 
in the younger age group and 76% of those in 
the older age group had either an abnormal 
CS or VEP (Figures 3, 4).
DISCuSSION
This study revealed that CS and VEP both 
detected the same rate of abnormalities in 
young patients with clinically definite MS. 
In contrast, VEP showed a far higher rate 
of abnormalities than CS in older subjects. 
Many other studies have shown the presence 
of subclinical alterations of the visual system 
in MS, but there is little agreement on the 
prevalence of these abnormalities or the most 
sensitive diagnostic tests.
Fahy et al4 compared CS impairment and 
VEP abnormalities among 39 patients with 
clinically definite multiple sclerosis and reported 
that CS was impaired in only 33% of patients 
while VEP was abnormal in 82%. Della Sala 
et al7 studied 48 multiple sclerosis patients 
using the same tests and found that 73% had 
abnormal CS and 82% had delayed VEP. Van 
Diemen et al8 evaluated the visual system in 
22 patients with clinically definite multiple 
sclerosis without visual symptoms. They found 
CS abnormalities in 72% and VEP abnormalities 
in 81%. Sisto et al3 evaluated subclinical visual 
involvement in multiple sclerosis among 11 
patients and reported abnormal CS in 17 (77.1%) 
and delayed VEP in 12 eyes (54.4%). Leys 
et al9 found an abnormal CS in only 50% and 
abnormal VEP in 94% of a total of 18 multiple 
sclerosis patients. Wender10 studied contrast 
Figure 4. The frequency of patients with abnormal CS, 
abnormal VEP and abnormal CS or VEP in the 30-49 year 
age group.
Figure 3. The frequency of patients with abnormal CS, 
abnormal VEP and abnormal CS or VEP in the 10-29 year 
age group.CS vs. VEP in Multiple Sclerosis; Heravian et al
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sensitivity in 100 patients with multiple sclerosis 
and found 59% had an abnormal CS. The large 
discrepancies in reported rates of CS and VEP 
abnormalities may be due to differences in 
examination methods and enrollment criteria.
According to our results, contrast sensitivity 
declines with age which is consistent with 
findings of previous studies. Ross et al11 studied 
the effect of age on contrast sensitivity among 
70 subjects and reported that as with a number 
of other visual functions, contrast sensitivity 
declines with age, particularly in medium 
and high spatial frequencies. Fahy et al4 also 
mentioned CS testing to be less productive 
over the age of 40. The possible mechanism 
suggested by Elliott et al12 was neural loss 
within visual pathways with increasing age. 
Morrison and McGrath13 concluded that age-
related deterioration is primarily caused by 
changes within the central nervous system 
rather than the optical media, the transmission 
quality of which remains unaffected. Whitaker 
and Elliott14 also suggested that under normal 
conditions, neural factors primarily account for 
the deterioration in visual quality experienced 
by older subjects. However, it is still uncertain 
whether such changes are caused by retinal 
and neural cell loss and degeneration, or occur 
secondary to reduced retinal illumination due 
to senile pupillary miosis and increased lens 
absorption by the greater light scatter of the 
aged eye15. In young subjects, whose eyes have 
not yet shown the effects of aging, deficits in 
contrast sensitivity resulting from retrobulbar 
pathology may be more apparent than the 
elderly, in whom ocular factors play a relatively 
important role7.
Our findings demonstrated that binocular 
contrast sensitivity testing provides a better 
measure of MS-related visual dysfunction 
than the monocular test over the age of 30 
years. However, binocular and monocular 
CS detected the same rate of abnormalities in 
subjects less than 30. According to our results, as 
monocular contrast threshold increases by age, 
binocular summation appears to become more 
appreciable in older subjects. In contrast, Owsley 
et al16 demonstrated that younger observers 
manifest binocular summation effects greater 
than older observers. Pardhan17 compared 
binocular and monocular contrast sensitivity 
in young and elderly observers for sinusoidal 
gratings of 1 and 6 cycle/degree. This study 
also found lower binocular summation effects 
at both spatial frequencies for older subjects. It 
is noteworthy that in both studies mentioned 
above, healthy observers with different age 
ranges were assessed and different contrast 
sensitivity tests were employed.
We found no significant change in VEP 
abnormalities as a function of age, which 
supports previous studies. According to a 
study by Mitchell and Neville18, the visual 
pathway shows little age related change from 
young adulthood to middle ages (20-60 years). 
Della Sala et al7 also found no marked change 
in VEP abnormalities with age. In contrast, 
Tubimatsu et al19 showed the presence of a 
curvilinear relationship between P100 latency 
and age. The extent of the effect of age on 
VEP latency depends on stimulus parameters 
(luminance, contrast, and spatial frequency).20 
The increase in P100 latency with age is more 
apparent at lower levels of luminance and 
contrast. Moreover, the age-related latency 
effect is greater for high (small checks) than 
for low (large checks) spatial frequencies, 
therefore these factors may affect age-related 
changes in VEP.21 The visual system consists 
of multiple, parallel channels which process 
information and aging may differentially 
affect specific functional subdivisions in the 
visual pathways.21 Furthermore, some have 
concluded that the increase in VEP latency with 
aging occurs mainly in older age strata (after 
the fifth decade)22 and most of the patients in 
our study, even in the older age group, were 
younger than 45. According to our results, 
VEP is more likely to detect optic neuropathy 
in the older age group.
A significant association was found 
between abnormal contrast sensitivity and 
visual symptoms only in the young age group 
of 10-29. This was probably due to the fact that 
CS was abnormal in all symptomatic eyes in 
this age group. We found that CS was more 
sensitive in detecting clinical deficits in both 
age groups. In contrast, VEP detected more CS vs. VEP in Multiple Sclerosis; Heravian et al
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subtle subclinical deficits. Leys et al9 also 
concluded that VEP was more sensitive than 
CS at detecting occult visual loss in patients 
with multiple sclerosis.
Despite the fact that neither VEP nor CS 
could detect all cases of MS, when the two 
tests were taken together, 90% of patients in 
the young age group and 75% of the older age 
group had at least one abnormal test result. 
These findings support those of previous 
authors. Van Diemen et al8 reported that 
the combination of the two tests detected 
abnormalities in 90.9% of their subjects. In the 
Della Sala et al7 study, 95% of abnormalities 
were found after the two tests were performed 
together and thus, they considered CS testing as 
a useful supplementary test for the evaluation 
of patients with suspected multiple sclerosis. 
Burki22 studied VEP and CS in 49 patients with 
optic neuritis and 26 multiple sclerosis patients 
with no previous history of optic neuritis and 
concluded that combined testing with CS and 
VEP was superior to a single test and detected 
100% of acute optic nerve lesions.
According to our results, there was 
no significant correlation between VEP 
abnormalities and CS impairment, which is 
consistent with findings reported in previous 
studies.7,8 One possible explanation is that these 
tests measure different aspects of visual function. 
Therefore, the combination of the two tests can 
improve the detection of visual dysfunction 
in both symptomatic and asymptomatic eyes.
The Cambridge Low Contrast Grating test 
is inexpensive, portable, easy to score, and can 
examine contrast sensitivity in any meridian. 
It has the potential disadvantage of measuring 
contrast sensitivity at only one spatial frequency. 
On rare occasions, sensitivity loss can be more 
marked in certain spatial frequencies and any 
test that examines only one spatial frequency 
may therefore, in principle be less sensitive 
than those that examine the entire frequency 
spectrum5. This may explain the lower rate of 
abnormal contrast sensitivity in our report, in 
comparison to previous studies.
We may conclude that the Cambridge Low 
Contrast Grating test is a useful test to detect 
clinical and subclinical visual dysfunction, 
especially in young patients with multiple 
sclerosis. Nevertheless, the combination of CS 
and VEP enables detection of most cases of 
visual dysfunction in patients with clinically 
definite MS.
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